A type of brain-targeting nano-formulation and its anti-tumour effect in paediatric brain tumour cells

Xin Tiana Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Taoxiang Shia Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, ChinaView further author information

Shiyang Fua Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, ChinaView further author information

Zheda Liua Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, ChinaView further author information

Yalan Youa Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Keke Chena Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Anqi Yaoa Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Chengguang Zhua Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Minhui Zenga Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Wenfang Tanga Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialView further author information

Xiaojun Taoa Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, ChinaCorrespondence[email protected]
View further author information

Xiangling Hea Department of Pediatric Hematology and Oncology, Children’s Medical Center of Hunan Provincial People’s Hospital of The First Affiliated Hospital (X.T., Y.Y., K.C., A.Y., C.Z., M.Z., X.H.); and School of Medicine (T.S., S.F., Z.L., W.T., X.T.), Hunan Normal University, Changsha 410081, China;b Department of Hematology and Oncology, Children’s Medical Center, Hunan ProvincialCorrespondence[email protected]
View further author information

show all

ABSTRACT

In this study, we grafted cholesterol with pullulan to synthesize hydrophobic pullulan(CHP). Three CHP polymers (CHP1, CHP2, and CHP3), with different degrees of substitution were designed by changing the feed ratio of cholesterol to pullulan. The ¹H-NMR results showed that the hydrophobic substitutability of CHP1, CHP2, and CHP3 were calculated to be 8.26%, 5.67%, and 3.52%, respectively. The sizes of CHP1 NPs, CHP2 NPs, and CHP3 NPs were (118±7.9), (123±4.7) and (158±9.3) nm, respectively. The CHP NPs embedded with VCR and adsorbed Tween 80 (CHPT@VCR NPs). The results of microscale thermal imaging (MST) testing indicated the CHP-1 NPs with the highest degree of cholesterol substitution possessed the highest adsorption capacity for Tween 80. In vitro pharmacological studies were conducted in SJ-GBM2 cells, the results showed that the tumor cells inhibition rate and the cellular uptake rate of CHPT@VCR-1 NPs were the highest compared with CHPT@VCR-2 NPs and CHPT@VCR-3 NPs.

KEYWORDS:

Acknowledgments

The authors gratefully acknowledge the support of the Development Fund of Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This study was supported by the Science and Technology Innovation Project of Hunan Province [2018SK21216] and Research Program of Health Committee of Hunan Province [202106010330] to Xiangling He; Natural Science Foundation of Hunan Province of China [2021JJ40295] to Yanlan You; the National Innovation and Entrepreneurship Training Program for College Students [S202310542064] to Shiyang Fu; and Hunan Province College Student Innovation and Entrepreneurship Project [S202310542076] to Zheda Liu.

A type of brain-targeting nano-formulation and its anti-tumour effect in paediatric brain tumour cells

Information for

Open access

Opportunities

Help and information

A type of brain-targeting nano-formulation and its anti-tumour effect in paediatric brain tumour cells

ABSTRACT

Acknowledgments

Disclosure statement

Additional information

Funding

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature